ICD-10-CM Coding for HER2-Positive, Hormone Receptor-Negative Breast Cancer with Pulmonary Metastases
For this clinical scenario, assign the following ICD-10-CM codes: C50.412 (malignant neoplasm of upper outer quadrant of left female breast), C78.00 (secondary malignant neoplasm of unspecified lung), and Z17.0 (estrogen receptor negative status [ER-]).
Primary Site Coding
The primary malignancy requires C50.412 specifically for the upper outer quadrant of the left breast. This anatomically precise code is essential for accurate documentation of the tumor location 1, 2.
Metastatic Disease Coding
The bilateral pulmonary nodules represent metastatic disease and require C78.00 (secondary malignant neoplasm of unspecified lung). When bilateral lung metastases are present without specification of which lung is more involved, C78.00 is the appropriate code. If documentation specifies right versus left lung predominance, use C78.01 or C78.02 accordingly 1.
Receptor Status Coding
Hormone Receptor Status
Z17.0 must be assigned to document estrogen receptor-negative status. This is a critical biomarker that fundamentally alters treatment decisions 3, 4, 2. While progesterone receptor status wasn't explicitly mentioned in your scenario, if documented as negative, also assign Z17.1 (estrogen receptor positive status [ER+]) - note this would only apply if PR status differs from ER status.
HER2-Positive Status
There is currently no specific ICD-10-CM code for HER2-positive status. This represents a significant gap in the coding system, as HER2 status is one of the most therapeutically relevant biomarkers in breast cancer 5, 6. HER2-positive disease fundamentally changes treatment algorithms, with anti-HER2 therapies like trastuzumab, pertuzumab, and trastuzumab deruxtecan being standard of care 7, 5, 4.
Document HER2-positive status in the clinical narrative since it cannot be captured with a diagnosis code. This ensures the critical therapeutic implications are communicated even though coding limitations exist.
Clinical Context and Treatment Implications
This coding combination identifies a patient with metastatic HER2-positive, hormone receptor-negative breast cancer - a distinct biological subtype requiring HER2-directed therapy combined with chemotherapy 3, 7, 4. The hormone receptor-negative status means endocrine therapy would be inappropriate 3, 8, 9.
Key Coding Principles
- Always code both the primary site and metastatic sites when metastatic disease is present
- Receptor status codes (Z17.x) are supplementary but mandatory for breast cancer given their treatment implications 10, 4, 2
- Anatomic precision matters: Use the most specific site code available (C50.412 rather than C50.9)
- Bilateral metastases: When both lungs are involved without laterality specification, C78.00 is correct
Common Pitfalls to Avoid
- Do not use C50.919 (malignant neoplasm of unspecified site of unspecified female breast) when the specific quadrant is documented
- Do not omit Z17.0 - receptor status is not optional documentation for breast cancer
- Do not code the pulmonary nodules as primary lung cancer - these are metastases (C78.x), not primary lung malignancies (C34.x)
- Do not assume HER2 status can be coded - it must be documented in clinical notes instead
Staging Considerations
While not diagnosis codes per se, this clinical picture represents Stage IV (metastatic) disease given the distant pulmonary metastases 10, 1, 4. This stage designation drives treatment intensity and prognosis discussions, with median survival significantly improved by modern HER2-targeted therapies 7, 5.
The absence of a HER2-specific ICD-10-CM code remains a notable limitation given that HER2 status is as therapeutically relevant as hormone receptor status in determining treatment pathways 5, 6, 4.